Abstract: The Graph Isomorphism problem regained interest with the rise of Graph Neural Networks (GNN). These GNN models have limited ability to distinguish between isomorphic graphs and hence their ...
CEO Sam Altman called a strange graph in its GPT-5 presentation a ‘mega chart screwup.’ CEO Sam Altman called a strange graph in its GPT-5 presentation a ‘mega chart screwup.’ is a senior reporter ...
ABSTRACT: To effectively evaluate a system that performs operations on UML class diagrams, it is essential to cover a large variety of different types of diagrams. The coverage of the diagram space ...
Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...
In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed ...
This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. As Isomorphic Labs aims its artificial ...
Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...
In the age when data is everything to a business, managers and analysts alike are looking to emerging forms of databases to paint a clear picture of how data is delivering to their businesses. The ...
On a rare sunny day in London at the Google DeepMind office, Colin Murdoch saw the bank deposit from his employer come through. It wasn't his paycheck. Google was investing in his startup. The ...
eSpeaks' Corey Noles talks with Rob Israch, President of Tipalti, about what it means to lead with Global-First Finance and how companies can build scalable, compliant operations in an increasingly ...
March 31 (Reuters) - Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ever external funding round led by Thrive Capital, the ...
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised external capital for the first time. The $600 million round was led by Thrive Capital, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback